Literature DB >> 12437940

The role of glutamate and gamma-aminobutyric acid in fear extinction: clinical implications for exposure therapy.

Michael Davis1, Karyn M Myers.   

Abstract

Although much is now known about the neural basis of fear acquisition, the mechanisms of fear inhibition or suppression remain largely obscure. Fear inhibition is studied in the laboratory through the use of an extinction procedure, in which an animal (typically a rat) is exposed to nonreinforced presentations of a conditioned stimulus (CS; e.g., a light or tone) that had previously been paired with a fear-inducing unconditioned stimulus (US; e.g., a mild footshock). Over the course of such training, the conditioned fear response exhibited by the rat in the presence of the CS is reduced in amplitude and frequency. This procedure is analogous to those employed in the treatment of fear dysregulation in humans, which typically involve exposure to the feared object in the absence of any overt danger. Recent work on the neural basis of extinction indicates that the neurotransmitters gamma-aminobutyric acid (GABA) and glutamate are critically involved. Gamma-aminobutyric acid may act to inhibit brain areas involved in fear learning (e.g., the amygdala), and glutamate, acting at N-methyl-D-aspartate receptors, may play a role in the neural plasticity that permits this GABA-mediated inhibition to be exerted appropriately. These insights have significant implications for the conduct of extinction-based clinical interventions for fear disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12437940     DOI: 10.1016/s0006-3223(02)01507-x

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  52 in total

1.  Lithium monotherapy associated clinical improvement effects on amygdala-ventromedial prefrontal cortex resting state connectivity in bipolar disorder.

Authors:  Murat Altinay; Harish Karne; Amit Anand
Journal:  J Affect Disord       Date:  2017-06-27       Impact factor: 4.839

Review 2.  Molecular specificity of multiple hippocampal processes governing fear extinction.

Authors:  Jelena Radulovic; Natalie C Tronson
Journal:  Rev Neurosci       Date:  2010       Impact factor: 4.353

3.  Extinction requires new RNA and protein synthesis and the soma of the cell right pedal dorsal 1 in Lymnaea stagnalis.

Authors:  Susan Sangha; Andi Scheibenstock; Ross Morrow; Ken Lukowiak
Journal:  J Neurosci       Date:  2003-10-29       Impact factor: 6.167

4.  Factors regulating the effects of hippocampal inactivation on renewal of conditional fear after extinction.

Authors:  Kevin A Corcoran; Stephen Maren
Journal:  Learn Mem       Date:  2004 Sep-Oct       Impact factor: 2.460

5.  Effects of a Rhodiola rosea L. extract on the acquisition, expression, extinction, and reinstatement of morphine-induced conditioned place preference in mice.

Authors:  Laura Mattioli; Federica Titomanlio; Marina Perfumi
Journal:  Psychopharmacology (Berl)       Date:  2012-03-16       Impact factor: 4.530

6.  Combined use of behavioral therapy and partial NMDA agonist to treat anxiety disorders.

Authors:  Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

7.  Different mechanisms of fear extinction dependent on length of time since fear acquisition.

Authors:  Karyn M Myers; Kerry J Ressler; Michael Davis
Journal:  Learn Mem       Date:  2006 Mar-Apr       Impact factor: 2.460

8.  Time-dependent retrograde amnesic effects of muscimol on conditioned taste aversion extinction.

Authors:  Anthony Disorbo; Gina N Wilson; Stephanie Bacik; Zana Hoxha; Jaclyn M Biada; G Andrew Mickley
Journal:  Pharmacol Biochem Behav       Date:  2009-01-10       Impact factor: 3.533

Review 9.  Developmental rodent models of fear and anxiety: from neurobiology to pharmacology.

Authors:  Despina E Ganella; Jee Hyun Kim
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

10.  Augmentation of exposure therapy with post-session administration of D-cycloserine.

Authors:  Candyce D Tart; Pamela R Handelsman; Lindsey B Deboer; David Rosenfield; Mark H Pollack; Stefan G Hofmann; Mark B Powers; Michael W Otto; Jasper A J Smits
Journal:  J Psychiatr Res       Date:  2012-10-23       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.